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among children and adolescents.METHODS: The primary data source is the Mar-
ketScanMedicaid database from 2002 to 2007. A total of 783,368 patients (ages 0-18)
with asthma were selected and divided into two cohorts: 405,941 with newly-diag-
nosed asthma and 377,427 with pre-existing asthma. Drug use was tracked of
inhaled corticosteroids (ICSs), LABAs, ICS/LABA combination drugs, short-acting
beta agonists (SABAs), leukotriene modifiers, and oral and IV steroids. Cox propor-
tional hazard regressionswere estimated to assess the risk of SAEs associatedwith
different drug regimens. RESULTS: Approximately 9.5% patients were hospitalized
or received intubation, while 60.8% visited the emergency department (ED). Hazard
ratios of ED visits for newly-diagnosed and pre-existing-asthma patients were as
follows: 0.60 (0.53-0.69) and 0.68 (0.62-0.75) for patients on a LABAwithout ICS; 0.69
(0.67-0.72) and 0.77 (0.75-0.80) for those on a LABA/ICS single inhaler; and 1.43
(1.41-1.45) and 1.33 (1.31-1.34) for AfricanAmericans, respectively. Hazard ratios for
hospitalization or intubation for newly-diagnosed and pre-existing-asthma pa-
tients were as follows: 0.43 (95% CI 0.22-0.84) and 1.30 (0.96-1.76) for patients on a
LABAwithout ICS; 1.19 (1.05-1.36) and 1.65 (1.45-1.89) for those on a LABA/ICS single
inhaler. Other key risk factors (p0.0001) included an alcohol/substance abuse
disorder, pregnancy, obesity, and upper respiratory tract infection.CONCLUSIONS:
Relative to SABA-only therapy, LABA use is associatedwith a lower risk of ED visits.
Certain patients with asthma, such as pregnant adolescents and African Ameri-
cans, are particularly vulnerable to SAEs.
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OBJECTIVES: The purpose of this study is to determine whether there is an in-
creased prevalence of OLD in patients with obstructive sleep apnea (OSA).
METHODS: The prevalences of COPD, asthma, and COPD combined with asthma
(ICD-9 coding) were compared between 1497 adult OSA patients and a 1489 control
patients, matched for age, gender, geographic location, and primary care physi-
cian. Co-morbidity burden was assessed using the Charlson Co-morbidity Index
(CCI). The prevalences of specific co-morbidities were measured in the OLD groups
between patients with OSA and the matched control group. RESULTS: COPD,
asthma and COPD combined with asthmawere found to bemore prevalent among
OSA patients compared to thematched controls. Prevalences among patients with
andwithout OSA respectivelywere: COPD: 7.6%, 3.7%(P .0001); asthma: 10.4%, 5.1
% (P  .0001), COPD plus asthma: 3.3%, 0.9% (p  .0001). CCI was greater for OSA
patients (2.3  0.2) than for controls (1.9  1.8; p  .0001). These trends held for all
severity ranges of OSA. For patients with COPD, OSA was associated with greater
prevalence of diabetes (50.9% vs. 22%, p0.004) and obesity (78.9% vs. 31.7%, p 
0.0001). Patients with OSA and COPDwere characterized bymore severe hypoxia at
night compared with the OSA patients without OLD. CONCLUSIONS: OSA was
associatedwith increased prevalence of OLDs. This was true for COPD, asthma and
patients with both diagnoses. Further, increased prevalence rates of OLD were
found in all ranges of OSA severity.
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BACKGROUND: Omalizumab is licensed as an add-on therapy for the treatment of
uncontrolled severe allergic asthma. It was granted reimbursement by the French
National Health Pricing Authority – The Economic Committee on Health Care Prod-
ucts (CEPS), under the provision that the manufacturer committed to conducting
an independent comparative-effectiveness study to demonstrate improved out-
comes for patients taking omalizumab in real-life settings. OBJECTIVES: To assess
whether the use of omalizumab as an add-on therapy for uncontrolled severe
asthma was associated with a decreased risk of hospitalization and emergency
room visits (HERV) due to asthma exacerbations.METHODS:A ‘before-after cohort’
methodologywas used to assess the relative effectiveness of omalizumab. A cohort
of adult patients with uncontrolled severe asthma, free of omalizumab at entry,
was recruited from 163 pulmonary medicine centers and observed naturalistically
over 2 years, before-after the introduction and use of omalizumab. The relative rate
of HERV was assessed using a Cox time-varying regression model with Prentice–
Williams-Gill correction for auto-correlated data (SAS-GENMOD). Results were ad-
justed using propensity scores for all potential confounders including the history of
hospitalization, corticosteroid use, smoking history, allergy history and others.
RESULTS:The cohort recruited 767 patients, ofwhom374 took omalizumab at least
once. Omalizumabusewas associatedwith an adjusted relative risk of HERVof 0.56
(95% CI: 0.43-0.74) when compared to non-use as a whole and 0.40 (95% CI: 0.28-
0.58) when only omalizumab users are considered before-after introduction of the
drug.CONCLUSIONS:A before-after cohortmethodology ensured a successful cov-
eragewith evidence development of a new drug in the treatment of severe asthma.
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OBJECTIVES: This review aims to identify risk factors for mortality among patients
with chronic obstructive pulmonary disease (COPD). METHODS: We searched
PubMeddatabase using the terms: “pulmonary disease, chronic obstructive”, “mor-
tality”, “risk factors” and “predictor”. We included only studies among patients
with a primary diagnosis of COPD and excluded non-English publications, litera-
ture reviews or editorials. RESULTS: We initially identified 335 articles, among
which 60 articles met inclusion criteria. We found seven additional studies from
the references. Key risk factors formortality (# significant vs non-sigificant studies)
were: 1) Forced expiratory volume per second (FEV1) (14 vs 19), dyspnea (3 vs 4),
partial arterial carbon dioxide tension (5 vs 12), and partial pressure of oxygen (5
vs13); 2)Charlson comorbidity index (7 vs 8); 4) disease severity index: Global ini-
tiative for Obstructive LungDisease stage (3 vs 2) andAcute Physiology andChronic
Health Education II score (3 vs 1); 5) quality of life (QoL): St George’s Respiratory
Questionnaire score(6 vs 2); 6)malnutrition: Bodymass index (BMI) (7 vs 22) and Fat
free mass index (2 vs 2); 7) previous hospitalization (10 vs 5); 8) inflammatory
marker (7 vs 3); 9) Age (26 vs 18) and smoking (5 vs 8). Only 9 studies implemented
a multidimensional risk indexes (MRIs) such as the BODE (BMI, Obstructive, Dys-
pnea, and Exercise Capacity) index, REFI (Respiratory Functional Impairment) in-
dex and PILE (FEV1%, interleukin-6, and knee extensor strength) score, and all
studies found that MRIs were predictive of mortality HADO score and PILE score,
which displayed more strength and advantage in predicting mortality than using
the single factor as no study was found where use of an MRI was not predictive.
CONCLUSIONS: Age, QoL, previous hospitalization, comorbidities, and inflamma-
tory markers were more consistently found to be risk factors. Multidimensional
risk scores should be used to assess mortality risk when possible.
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OBJECTIVES: Tobacco use remains the leading preventable cause of premature
death worldwide. In the Middle East, tobacco use continues to increase with re-
ported smoking rates ranging from 40-60%. The objectives were to determine the
rate of cigarette smoking among a sample of adults in Jordan, a small Middle
Eastern country, and correlates of its use. METHODS: A cross-sectional survey
designwas conducted in a convenience sample of adults inAmman, Jordan. Survey
questions included socio-demographic characteristics, current and history of to-
bacco smoking, environmental and behavioral determinants of smoking. Three
multivariate logistic regression models were constructed to determine predictors
of cigarette use with the following outcomes: past 30-day use vs. no use (model 1),
past 7-day use vs. no use (model 2), and past 24-hour use vs. no use (model 3). All
analyses were carried out using SAS 9.2. RESULTS: A total of 600 participants com-
pleted survey. Approximately half of the samplewas female (51.56%) and themean
age was 27 years. Past 30-day cigarette use was reported in 45% of the population,
while 41% reported smoking a cigarette in the past 7 days, andmore than one third
(36%) in the past 24 hours. Male gender (OR 4.475model 1, OR 7.456model 2, OR
20.578 model 3), age older than 25 (OR  2.952 model 1, OR  5.256 model 2, OR 
8.165 model 3), lower education level (OR  7.128 model 1, OR  9.766 model 2,
OR 8.265model 3), and past cigar use (OR 3.405model 1, OR 4.339model 2, OR
 2.669model 3) were significant predictors of cigarette smoking. Participants who
were satisfied with their health were less likely to be smokers (OR 0.231 model 2,
OR 0.243model 3).CONCLUSIONS: The findings underscore themagnitude of the
smoking problem in the general population in Jordan and the urgent need for
effective prevention and intervention strategies. Future research should focus on
developing intervention strategies that incorporate the predictors identified above.
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OBJECTIVES:Waterpipe smoking is a new trend in tobacco use with a growing pop-
ularity and unsubstantiated belief that the practice is safe. The objectives were to
determine the rate of waterpipe smoking among a sample of adults in Jordan and
correlates of its use.METHODS: A cross-sectional survey was administered in a con-
venient sample of adults in Amman, Jordan (n  600). Survey included socio-demo-
graphic characteristics, current and history of tobacco smoking, environmental and
behavioral smoking determinants like peer influence, and perceived harm. Three
multivariate logistic regression models were constructed to determine predictors of
waterpipeuse for the followingoutcomes: previous lifetimeuseofwaterpipe to smoke
tobacco vs. no use (model 1), previous 30-day use vs. no use (model 2), and previous
7-day use versus nouse (model 3). Resultswere presented as adjusted odds ratios (OR)
with 95% confidence intervals (CI). All analyses were carried out using SAS statistical
package version 9.2.RESULTS: The sample consisted of 51.56% femalewithmean age
of 27 years. More than half of the sample (53%) had previously smoked tobacco using
a waterpipe, a third during the past month (33.94%), and 22% during the past week.
Previous cigarette use (OR  6.37 model 1, OR  3.38 model 2, OR  4.29 model 3),
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